Changes in Degree Centrality and Functional Connectivity after the First Cycle of Neoadjuvant Chemotherapy in Newly Diagnosed Breast Cancer: A Longitudinal Study

Table 1

Clinical characteristics.

Characteristics	NAC group	HC group	value
	()	()
Age (years)			0.78
Education (years)			0.31
BMI (TP0)			0.32
Hypertension/nonhypertension (TP0)	6/29	3/27	0.49
Premenopausal/postmenopausal (TP0)	14/21	14/16	0.59
Stage
cIIA/cIIB	2/4	N/A	N/A
cIIIA/cIIIb/cIIIc	17/5/7	N/A	N/A
Regimen
AC-T	9	N/A	N/A
EC-T	3	N/A	N/A
TCbHP	7	N/A	N/A
TCbHB	4	N/A	N/A
TAC	12	N/A	N/A

Distribution data are reported as . For the intergroup comparisons of age, education, and BMI, the value was obtained using the independent sample -test. For the intergroup comparisons of blood pressure and menstrual status, the value was obtained using the test. Abbreviations: BMI: body mass index; AC-T: epirubicin, cyclophosphamide, and paclitaxel; EC-T: doxorubicin, cyclophosphamide, and paclitaxel; TCbHP: paclitaxel, carboplatin, pertuzumab, and trastuzumab; TCbHB: paclitaxel, carboplatin, trastuzumab, and pyrotinib; TAC: docetaxel, doxorubicin, and cyclophosphamide; N/A: not applicable.